THALES
A major new survey by Thales shows that two out of three Europeans citizens are looking forward to the arrival of an EU-backed Digital ID Wallet for storing their ID card, driving licence and other official documents and signed attestations on a smartphone. The results also reveal that while 27% currently use some form of official national Digital ID scheme, 45% are relying on insecure, unofficial, ‘DIY’ (do it yourself) scans and photos of their cards and documents to help prove their identity and entitlements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220605005010/en/
Digitalisation is already improving user-experience and relieving identification headaches
Starting with a pilot phase in 2023, every member state must by 2024 offer citizens a Digital ID Wallet that can be used throughout the EU. The results of the survey certainly underline the need for this pioneering European initiative aiming at offering most convenient User Experience (UX) at highest level of security. Regarding UX, 34% of people surveyed currently find it difficult to prove their identity when renewing an ID document, 30% have problems when making a high value purchase, and 29% encounter troubles when applying for financial services. However, among the 40% who face such issues, the figure falls to just 5% or below when a digital format is used.
Successful wallets will need to match highest security standards
In all but one of the countries surveyed, government emerges as the preferred provider of the EDIW. However, despite widespread public support for the idea, the results demonstrate that wallet providers must address significant security and data privacy concerns among potential users. In particular, the research shows that 65% of Europeans rate security as the most important feature in any new wallet, followed by convenience and privacy.
Results highlight different national attitudes to the EDIW
The survey uncovers differences in national attitudes. The French and the Italians are the most positive about the EDIW, with 85% and 75% respectively claiming they will use it. Enthusiasm for the EDIW is also influenced by age, and citizens’ experiences of digital wallets providers (such as Apple, Google, Samsung) and national Digital ID schemes including BankID in Sweden.
“By providing citizens with a secure and convenient means of proving their identity and entitlements via a smartphone, the EDIW will enable smooth and secure interactions between citizens, governments and private businesses. The results of our survey offer providers a better understanding of citizens’ needs, helping them to maximise adoption and use of the new wallets that will be introduced throughout the EU over the next 18 months. Thales as a leader in digital security and trustful provider of digital identities remains fully committed to address those needs thanks to field-proven wallet solutions,” said Youzec Kurp, VP Identity and Biometric Solutions at Thales.
Conducted by Thales, the survey took place in December 2021. In total, 1835 citizens from seven different EU countries provided detailed answers to an online questionnaire. The full results are now available in a new white paper: Understanding the European identity experience.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The company provides solutions, services and products that help its customers — businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
Thales Group
Market page
Download HD photos
@Thalesgroup
View source version on businesswire.com: https://www.businesswire.com/news/home/20220605005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom